TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03162276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR) program
Description: The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
Study: NCT04160260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: Omadacycline: PO Tablets
Study: NCT04341038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: the necessary dose to obtain blood levels of 8-10 ng / ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 120mg of methylprednisolone daily for 3 consecutive days
Study: NCT03113591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimum invasive total hip arthroplasty
Description: Minimum invasive total hip arthroplasty using the osteo introducer system
Study: NCT01015456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate sodium
Description: per oral, twice daily, for 12 months
Study: NCT03113591

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Common total hip arthroplasty
Description: Common total hip arthroplasty using common instruments
Study: NCT01015456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: intravenous, monthly, for 6 months
Study: NCT02960984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Oriented rehabilitation and aerobic training
Description: Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
Study: NCT04074122

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine and epinephrine, isoprenaline provocation
Description: High-resolution electromechanical mapping at baseline and after provocative measures.

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine and epinephrine, isoprenaline provocation
Description: High-resolution electromechanical mapping at baseline and after provocative measures.
Study: NCT01352520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-35
Description: 1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
Study: NCT03837496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRIDE
Description: STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STRIDE
Description: STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
Study: NCT04074122

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine and epinephrine, isoprenaline provocation
Description: High-resolution electromechanical mapping at baseline and after provocative measures.
Study: NCT03837496

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Monitoring Control
Description: Care provided as standard by the hospital and medication monitoring
Study: NCT00448058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK372475
Description: daily administration during the 10-week treatment phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine
Description: daily administration during the 10-week treatment phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily administration during the 10-week treatment phase
Study: NCT01115426

Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril or losartan
Description: Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
Study: NCT03728803

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold IMT, Philips Respironics, Murrysville, PA, USA
Description: Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Threshold IMT, Philips Respironics, Murrysville, PA, USA
Description: Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
Study: NCT02598349

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
Study: NCT01999010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHT
Description: MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHT
Description: MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
Study: NCT02803697

Intervention type: OTHER
Intervention: Patients
Study: NCT03300245

Intervention type: RADIATION
Intervention: Maxillofacial CT
Description: clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
Study: NCT01338116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antibiotic treatment of by TREAT/PCR
Description: Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
Study: NCT00536367

Intervention type: OTHER
Intervention: No intervention - observational study only
Study: NCT00128258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of bone marrow cells in the heart
Description: Biological implant into the heart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological bone marrow cell therapy
Description: Biological implant into the heart
Study: NCT02653677

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intake of the specific kind of bread
Description: To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intake of the specific kind of bread
Description: To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intake of the specific kind of bread
Description: To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intake of the specific kind of bread
Description: To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
Study: NCT02490137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Race Car Video Game
Description: Repeatedly playing a race car video game
Study: NCT03191903

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Hyaluronic Acid with Triamcinolone Hexacetonide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monovisc
Description: Hyaluronic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Hexacetonide
Description: Triamcinolone Hexacetonide
Study: NCT02791815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral dose of 7.5 mg midazolam (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single oral dose of 7.5 mg midazolam (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
Study: NCT03224234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulclock with feedback
Description: Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulclock without feedback
Description: Not feedback on insulin administration.
Study: NCT01328002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets daily
Study: NCT00813761

Intervention type: DEVICE
Group type: OTHER
Intervention: O2Optix contact lens
Description: control contact lens to be worn daily for approximately 7 months for entire length of study.

Intervention type: DEVICE
Group type: OTHER
Intervention: O2Optix contact lens
Description: control contact lens to be worn daily for approximately 7 months for entire length of study.

Intervention type: DEVICE
Group type: OTHER
Intervention: O2Optix contact lens
Description: control contact lens to be worn daily for approximately 7 months for entire length of study.

Intervention type: DEVICE
Group type: OTHER
Intervention: O2Optix contact lens
Description: control contact lens to be worn daily for approximately 7 months for entire length of study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Proclear contact lens
Description: control contact lens to be worn for entire length of study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Proclear contact lens
Description: control contact lens to be worn for entire length of study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Proclear contact lens
Description: control contact lens to be worn for entire length of study.

Intervention type: DEVICE
Group type: OTHER
Intervention: Proclear contact lens
Description: control contact lens to be worn for entire length of study.

Intervention type: DEVICE
Group type: OTHER
Intervention: ReNu MultiPlus Multi-Purpose Solution
Description: lens solution for overnight lens disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: ReNu MultiPlus Multi-Purpose Solution
Description: lens solution for overnight lens disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: ReNu MultiPlus Multi-Purpose Solution
Description: lens solution for overnight lens disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: ReNu MultiPlus Multi-Purpose Solution
Description: lens solution for overnight lens disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: Clear Care Cleaning and Disinfecting Solution
Description: lens solution for overnight lens disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: Clear Care Cleaning and Disinfecting Solution
Description: lens solution for overnight lens disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: Clear Care Cleaning and Disinfecting Solution
Description: lens solution for overnight lens disinfection

Intervention type: DEVICE
Group type: OTHER
Intervention: Clear Care Cleaning and Disinfecting Solution
Description: lens solution for overnight lens disinfection
Study: NCT00452881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
Study: NCT04229862

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway insertion
Description: Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask airway insertion
Description: Laryngeal mask airway insertion in patients who undergoing transurethral bladder tumor resection
Study: NCT03194542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.
Study: NCT03989102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.
Study: NCT01222585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with \>=14 postnatal days and every 24 hours for infants \<14 postnatal days.
Study: NCT01443442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bepotastine besilate, 1.5%
Description: Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol etabonate
Description: Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
Study: NCT03339518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIM3 educational intervention
Description: Breast Cancer risk education and counseling

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait List
Description: Booklet at the end of study
Study: NCT00732121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02799745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Oral
Study: NCT03176732

Intervention type: DEVICE
Intervention: Positive Airway Pressure
Description: Participants will use Positive Airway Pressure (PAP) treatment

Intervention type: DEVICE
Intervention: Positive Airway Pressure
Description: Participants will use Positive Airway Pressure (PAP) treatment

Intervention type: DEVICE
Intervention: Positive Airway Pressure
Description: Participants will use Positive Airway Pressure (PAP) treatment

Intervention type: DEVICE
Intervention: Positive Airway Pressure
Description: Participants will use Positive Airway Pressure (PAP) treatment
Study: NCT01507428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Fluoromisonidazole
Description: Undergo FMISO PET/CT (Correlative studies)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoromisonidazole
Description: Undergo FMISO PET/CT (Correlative studies)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo FMISO PET/CT (Correlative studies)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FMISO PET/CT (Correlative studies)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo radiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Adaptive Radiation Therapy
Description: Undergo individualized adaptive radiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo FMISO PET/CT (Correlative studies)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FMISO PET/CT (Correlative studies)
Study: NCT00648297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
Description: 80/5mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corzide® Tablets 80 mg/5 mg
Description: 80/5mg, single dose fed
Study: NCT01435005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Volume
Description: Moderate volume (150 minutes per week) aerobic exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Volume
Description: Participate in one-year high volume (300 minutes per week)aerobic exercise.